Chr. Hansen posts ‘strong’ H1 with organic revenue growth of 10%

By Nathan Gray

- Last updated on GMT

Chr. Hansen posts ‘strong’ H1 with organic revenue growth of 10%

Related tags Term

Food and nutrition bioscience firm Chr. Hansen says it is well positioned to deliver its ambitious full year targets, as it reports 10% organic revenue growth for the first half of its financial year.

The Danish firm, known for its portfolio of cultures, enzymes, probiotics and natural colours, said revenue of €501 million in the first half of its current financial year is 10% higher than the €443 million seen in the same period in the previous year.

With a solid performance in the first half of 2016/17, we are well positioned to deliver on our ambitions for the year​,” said CEO Cees de Jong.

He commented that the firms’ Food Cultures & Enzymes and Natural Colours divisions delivered strong organic growth and improved profitability. This was despite the financial impacts of a change in management in Food Cultures & Enzymes in Q2.

Revenue growth for Food Cultures & Enzymes, Health & Nutrition, and Natural Colours was reported at 9%, 10% and 11% respectively.

“With 13% organic growth in Q2, Health & Nutrition is now delivering growth in line with our long-term ambitions for this business area,” ​added de Jong. “However, the EBIT margin in Health & Nutrition is still below the level of last year, partly due to continued investments in R&D.”

The CEO said Chr Hansen is pleased with progress of long term growth initiatives – especially the technological progress in the human microbiome.

The company confirmed that it’s outlook for full year is unchanged, with revenue growth of between 8-10% expected, and a slight increase in EBIT margin.

Related news

Show more

Related products

show more

Whitepaper: Discover a new era in postbiotics

Whitepaper: Discover a new era in postbiotics

Content provided by DSM Nutritional Products | 28-Nov-2023 | White Paper

Postbiotic ingredients are set to open up a world of opportunities across the human health and nutrition industry, fueled by developing science demonstrating...

Taking Immune Support to a New Level

Taking Immune Support to a New Level

Content provided by AB Biotek Human Nutrition & Health | 30-Oct-2023 | White Paper

Patent-pending ABB C1® redefines immune support by addressing innate, acquired, and Trained Immunity. In 'ABB C1®: Training Now for Future Immune...

Related suppliers

Follow us

Products

View more

Webinars